Study of Olutasidenib and Temozolomide in HGG
Trial details
- Registry ID
- NCT06161974
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Olutasidenib and Temozolomide in HGGNCT06161974 | Rigel Pharmaceuticals | Phase 2 | Recruiting | 2029-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |